Market research
PEPG PepGen Ltd
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 206M
- P/E ratio
- Not available
- Analyst target
- 10.1875
- Dividend yield
- Not available
- Beta
- 1.97
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US7133171055
- Market cap
- 206M
- P/E ratio
- Not available
- Analyst target
- 10.1875
- Dividend yield
- Not available
- Beta
- 1.97
About
About PepGen Ltd
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the PEPG discussion.
No comments yet
Start a focused discussion about PEPG.